FDA accepts Roche ’s BLA for emicizumab to treat Haemophilia A

The US Food and Drug Administration (FDA) has accepted Roche ’s biologics licence application (BLA) and granted a priority review for emicizumab prophylaxis (preventative) to treat patients with Haemophilia A with factor VIII inhibitors.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news